Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer

Oncogene

Volumn 31, Issue 41, 2012, Pages 4460-4471

  Jalava, S E ^a   Urbanucci, A ^a   Latonen, L ^a   Waltering, K K ^a   Sahu, B ^b   Janne O A ^b   Seppala J ^a   Lahdesmaki H ^c   Tammela, T L J ^a   Visakorpi, T ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c AALTO UNIVERSITY   (Finland)

Author keywords

androgen independent; BTG2; hormone refractory; miR 32; neoplasia; prostatic

Indexed keywords

ANDROGEN; LUCIFERASE; MICRORNA 148A; MICRORNA 21; MICRORNA 221; MICRORNA 32; MICRORNA 590 5P; MICRORNA 99A; MICRORNA 99B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; ASSAY; B CELL TRANSLOCATION GENE 2; BINDING SITE; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE; GENE CONTROL; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PHOSPHOINOSITIDE 3 KINASE INTERACTING PROTEIN 1; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANDROGENS; BINDING SITES; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; MALE; MEMBRANE PROTEINS; MICRORNAS; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REGULATORY SEQUENCES, NUCLEIC ACID; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84867401829     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.624     Document Type: Article

References (47)

1. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F et al. (2008). Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170.
2. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S et al. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26: 4563-4571.
3. Bartel DP. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
4. Cai C, Wang H, Xu Y, Chen S, Balk SP. (2009). Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 69: 6027-6032.
5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39. (Pubitemid 38524696)
6. Courtney KD, Corcoran RB, Engelman JA. (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083.
7. Di Leva G, Croce CM. (2010). Roles of small RNAs in tumor formation. Trends Mol Med 16: 257-267.
8. Edwards J, Krishna NS, Grigor KM, Bartlett JM. (2003). Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89: 552-526.
9. Feldman BJ, Feldman D. (2001). The development of androgenindependent prostate cancer. Nat Rev Cancer 1: 34-45.
10. Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA et al. (2001). Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis. Carcinogenesis 22: 1271-1279. (Pubitemid 32737344)
11. Friedman RC, Farh KK, Burge CB, Bartel DP. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
12. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A et al. (2010). MiR-148a attenuates paclitaxel resistance of hormonerefractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285: 19076-19084.
13. Guo H, Ingolia NT, Weissman JS, Bartel DP. (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840.
14. Hong JW, Ryu MS, Lim IK. (2005). Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death. J Biol Chem 280: 21256-21263. (Pubitemid 40805688)
15. Hu XD, Meng QH, Xu JY, Jiao Y, Ge CM, Jacob A et al. (2011). BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity. Biochem Biophys Res Commun 404: 903-909.
16. Jalava SE, Porkka KP, Rauhala HE, Isotalo J, Tammela TL, Visakorpi T. (2009). TCEB1 promotes invasion of prostate cancer cells. Int J Cancer 124: 95-102.
17. Karvonen U, Kallio PJ, Jä nne OA, Palvimo JJ. (1997). Interaction of androgen receptors with androgen response element in intact cells. J Biol Chem 272: 15973-15979.
18. Kloosterman WP, Plasterk RH. (2006). The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450. (Pubitemid 44430905)
19. Langmead B, Trapnell C, Pop M, Salzberg SL. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10: R25.
20. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramä ki OR et al. (2010). Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 16: 2845-2851.
21. Linja MJ, Savinainen KJ, Saramä ki OR, Tammela TL, Vessella RL, Visakorpi T. (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555. (Pubitemid 32694958)
22. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435: 834-838. (Pubitemid 40839735)
23. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJLH, M-ller S, Trapman J et al. (2011). Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 31: 978-991.
24. Massard C, Fizazi K. (2011). Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17: 3876-3883.
25. Mö llerström E, Ková cs A, Lö vgren K, Nemes S, Delle U, Danielsson A et al. (2010). Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray. BMC Cancer 10: 296.
26. Murata T, Takayama K, Katayama S, Urano T, Horie-Inoue K, Ikeda K et al. (2010). miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 13: 356-361.
27. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. (2007). MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135. (Pubitemid 47037493)
28. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH et al. (2009). miR-21: an androgen receptorregulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69: 7165-7169.
29. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A et al. (2011). Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 30: 3962-3976.
30. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. (2008). Proliferating cells express mRNAs with shortened 30 untranslated regions and fewer microRNA target sites. Science 320: 1643-1647. (Pubitemid 351931255)
31. Saramä ki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. 2008. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14: 3395-3400.
32. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F et al. (2010). Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176.
33. Scher HI, Sawyers CL. (2005). Biology of progressive, castrationresistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis. J Clin Oncol 23: 8253-8261. (Pubitemid 46211563)
34. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rü diger T, Strö bel P et al. (2010). Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127: 394-403.
35. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. (2006). Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
36. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. (2009). The role of microRNA-221 and microRNA-222 in androgenindependent prostate cancer cell lines. Cancer Res 69: 3356-3363.
37. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
38. Thompson J, Lepikhova T, Teixido-Travesa N, Whitehead MA, Palvimo JJ, Jänne OA. (2006). Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription. EMBO J 25: 2757-2767. (Pubitemid 43980383)
39. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA et al. (2009). ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56: 275-286.
40. Urbanucci A, Sahu B, Seppä lä J, Larjo A, Latonen LM, Waltering KK et al. (2011). Overexpression of androgen receptor enhances the binding of the receptor to the chromatin. Oncogene 31: 2153-2163.
41. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C et al. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406.
42. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261. (Pubitemid 43271657)
43. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA et al. (2009). Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69: 8141-8149.
44. Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM et al. (2010). Androgen regulation of micro-RNAs in prostate cancer. Prostate 71: 604-614.
45. Winkler GS. (2010). The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol 222: 66-72.
46. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE et al. (2008). Model-based analysis of ChIP-Seq (MACS). Genome Biol 9: R137.
47. Zhu Z, He X, Johnson C, Stoops J, Eaker AE, Stoffer DS et al. (2007). PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein. Biochem Biophys Res Commun 358: 66-72. (Pubitemid 46719081)